SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.73%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.59B
AUM Growth
+$1.59B
(-6.3%)
Cap. Flow
+$23.5M
Cap. Flow
% of AUM
1.48%
Top 10 Holdings %
Top 10 Hldgs %
51.2%
Holding
86
New
16
Increased
31
Reduced
15
Closed
11
Top Buys
| 1 |
Edwards Lifesciences
EW
|
$66.9M |
| 2 |
Stryker
SYK
|
$65.7M |
| 3 |
RAPP
Rapport Therapeutics
RAPP
|
$45.4M |
| 4 |
Align Technology
ALGN
|
$29.7M |
| 5 |
Axsome Therapeutics
AXSM
|
$25M |
Top Sells
| 1 |
Merck
MRK
|
$85.9M |
| 2 |
Incyte
INCY
|
$75.6M |
| 3 |
argenx
ARGX
|
$58.8M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$45.5M |
| 5 |
Insulet
PODD
|
$32.1M |
Sector Composition
| 1 | Healthcare | 99.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $168M | 8.72% | 1,550,280 | – | – |
|
2
Vera Therapeutics
VERA
$1.38B
| $101M | 5.25% | 2,793,987 | – | – |
|
3
Ascendis Pharma
ASND
$11.8B
| $100M | 5.2% | 734,284 -19,748 | -3% | -$2.69M |
|
4
Novo Nordisk
NVO
$251B
| $92.7M | 4.82% | 649,541 +37,657 | +6% | +$5.38M |
|
|
5
Edwards Lifesciences
EW
$47.8B
| $66.9M | 3.48% | +724,225 | New | +$66.9M |
|
|
6
Stryker
SYK
$150B
| $65.7M | 3.41% | +193,084 | New | +$65.7M |
|
7
AstraZeneca
AZN
$248B
| $62.5M | 3.25% | 801,417 +204,704 | +34% | +$16M |
|
8
Dyne Therapeutics
DYN
$1.92B
| $57.4M | 2.98% | 1,625,703 -310,947 | -16% | -$11M |
|
|
9
Align Technology
ALGN
$10.3B
| $52.8M | 2.74% | 218,524 +123,046 | +129% | +$29.7M |
|
|
RAPP
10
Rapport Therapeutics
RAPP
$643M
| $45.4M | 2.36% | +1,951,562 | New | +$45.4M |
|
11
Syndax Pharmaceuticals
SNDX
$1.41B
| $44.2M | 2.3% | 2,153,669 +545,129 | +34% | +$11.2M |
|
12
Elanco Animal Health
ELAN
$9.12B
| $41.3M | 2.15% | 2,864,250 +308,703 | +12% | +$4.45M |
|
13
IDEAYA Biosciences
IDYA
$2.15B
| $40.4M | 2.1% | 1,151,528 +369,932 | +47% | +$13M |
|
14
Intuitive Surgical
ISRG
$170B
| $38.8M | 2.02% | 87,217 -53,663 | -38% | -$23.9M |
|
15
Alnylam Pharmaceuticals
ALNY
$58.5B
| $35.9M | 1.87% | 147,929 +44,893 | +44% | +$10.9M |
|
16
TG Therapeutics
TGTX
$4.65B
| $33.1M | 1.72% | 1,861,277 -123,685 | -6% | -$2.2M |
|
17
ArriVent BioPharma
AVBP
$776M
| $31.5M | 1.64% | 1,696,752 | – | – |
|
18
Idexx Laboratories
IDXX
$51.8B
| $31.1M | 1.62% | 63,862 -11,362 | -15% | -$5.54M |
|
19
Sarepta Therapeutics
SRPT
$1.78B
| $30.9M | 1.61% | 195,852 -31,636 | -14% | -$5M |
|
20
Y-mAbs Therapeutics
YMAB
$388M
| $26.5M | 1.38% | 2,194,278 | – | – |
|
|
21
Axsome Therapeutics
AXSM
$6.05B
| $25M | 1.3% | +310,198 | New | +$25M |
|
22
Cogent Biosciences
COGT
$1.69B
| $23.4M | 1.22% | 2,773,286 +372,515 | +16% | +$3.14M |
|
23
Soleno Therapeutics
SLNO
$3.6B
| $22.6M | 1.18% | 554,359 +403,584 | +268% | +$16.5M |
|
24
Savara
SVRA
$567M
| $21.6M | 1.12% | 5,358,918 +3,011,657 | +128% | +$12.1M |
|
25
Celldex Therapeutics
CLDX
$1.47B
| $20.3M | 1.05% | 547,707 -254,070 | -32% | -$9.4M |
|